

1 **No difference in retinal fluorescence after oral curcumin intake in amyloid**
2 **proven AD cases compared to controls**

3
4
5 Jurre den Haan¹, MD, PhD, Frederique J. Hart de Ruyter¹, MD, Benjamin Lochocki²,
6 PhD, Maurice A.G.M. Kroon³, PharmD, E. Marleen Kemper³, PharmD, PhD,
7 Charlotte E. Teunissen, PhD⁴, Bart van Berckel, MD, PhD⁵, Philip Scheltens, MD,
8 PhD¹, Jeroen J. Hoozemans, PhD⁶, Aleid van de Kreeke, MD, PhD⁷, Frank D.
9 Verbraak, MD, PhD⁸, Johannes F. de Boer, PhD^{2*}, Femke H. Bouwman, MD, PhD^{1*}.

10

11 ¹ Amsterdam UMC, location VUmc, Alzheimer Center, Neurology, Amsterdam, The Netherlands,

12 ² VU Amsterdam, Department of Physics, LaserLaB, The Netherlands

13 ³Amsterdam UMC, location AMC, Department of Pharmacy and Clinical Pharmacology, Amsterdam,
14 The Netherlands.

15 ⁴ Amsterdam UMC, location VUmc, Neurochemistry lab, Department of Clinical Chemistry, Amsterdam
16 Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands

17 ⁵ Amsterdam UMC, location VUmc, Department of Nuclear Medicine, Amsterdam, The Netherlands

18 ⁶ Amsterdam UMC, location VUmc, Department of Pathology, Amsterdam Neuroscience, The
19 Netherlands

20 ⁷ Amsterdam UMC, location AMC, Ophthalmology Department Amsterdam, The Netherlands

21 ⁸ Amsterdam UMC, location VUmc, Ophthalmology Department, Amsterdam, The Netherlands

22 ^{*}Equal contribution.

23

24

25

26

27

28

29

30 Corresponding author:

31 Femke Bouwman, MD, PhD

32 Alzheimer center Amsterdam, Department of Neurology

33 Amsterdam UMC

34 Mailbox 7057

35 1007 MB Amsterdam

36 The Netherlands

37 Phone: +31204440685

38 Fax: +31204448529

39 Email: femke.bouwman@amsterdamumc.nl

40

41

42 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

43 **Abstract**

44

45 **INTRODUCTION:**

46 Previous work showed the *in-vivo* presence of retinal amyloid in AD patients using
47 curcumin. We aimed to replicate these findings in an amyloid biomarker confirmed
48 cohort.

49

50 **METHODS:**

51 Twenty-six AD patients (age 66 (+9), MMSE \geq 17) and 14 controls (age 71(+12)) used
52 one of three curcumin formulations: Longvida[®], Theracurmin[®] and Novasol[®].
53 Plasma levels were determined and pre- and post- curcumin retinal fluorescence
54 scans were visually assessed in all cases and quantitatively assessed in a subset.

55

56 **RESULTS:**

57 Visual assessment showed no difference between AD patients and controls for pre-
58 and post-curcumin images. This was confirmed by quantitative analyses on a subset.
59 Mean conjugated plasma curcumin levels were 198.7 nM (Longvida[®]), 576.6 nM
60 (Theracurmin[®]) and 1605.8 nM (Novasol[®]).

61

62 **DISCUSSION:**

63 We found no difference in retinal fluorescence between amyloid confirmed AD cases
64 and control participants, using Longvida[®] and two additional curcumin formulations.
65 Additional replication studies in amyloid confirmed cohorts are needed to assess the
66 diagnostic value of retinal fluorescence as an AD biomarker.

67

68

69 **Background**

70 Alzheimer's disease (AD) research over the last decades enabled clinicians to
71 diagnose AD not only in the dementia end-stage but also in the prodromal and
72 preclinical stages using biomarkers for amyloid, tau and neurodegeneration [1, 2]. AD
73 pathology starts 15-20 years before symptom onset and is reflected by change of
74 biomarkers in the preclinical stage [1]. This time-interval provides a window of
75 opportunity for disease modifying drugs to potentially halt disease progression
76 towards the end stage of AD: dementia [3]. As currently used biomarkers are time
77 consuming, expensive and/or invasive, non-invasive easily accessible biomarkers are
78 urgently needed to diagnose AD in the earliest stages, enabling timely selection of
79 patients for trials and future medication.

80 The retina is an extension of the central nervous system and might provide such a
81 biomarker. As such the retina is increasingly studied for manifestations of AD as
82 potential non-invasive AD biomarkers. For example, retinal thinning, changes in
83 retinal vasculature and peripheral drusen have been described in AD patients [4-6].
84 More specifically related to AD pathology, three small studies reported visualization
85 of retinal amyloid beta deposits *in-vivo* using curcumin, a polipotent polyphenol with
86 fluorescent properties that binds to amyloid in post-mortem brain tissue [7-9]. The
87 presence of retinal amyloid beta deposits is however not unequivocally proven, since
88 we and other groups could not confirm amyloid beta deposits in post mortem retinal
89 tissue [10-14]. Moreover, curcumin is known for its low bioavailability, and while
90 several commercially available formulations enhancing curcumin plasma levels are
91 on the market, so far only one formulation (Longvida[®]) has been reported to visualize
92 retinal amyloid[7].

93 In the current study, we used three different curcumin formulations as labeling
94 fluorophores in-vivo. Using a targeted fluorescence approach, we aimed to visualize
95 retinal amyloid in a well-characterized and amyloid biomarker confirmed AD cohort.

96

97

98 **Methods**

99 *Participants*

100 We enrolled 26 patients with AD (MMSE score ≥ 17) and 14 controls (MMSE ≥ 27)
101 from two different cohorts – the Alzheimer Dementia Cohort (ADC) and the EMIF-AD
102 PreclinAD study. All subjects underwent extensive screening according to a
103 standardized protocol described elsewhere [15, 16]. All patients fulfilled NIA-AA
104 criteria of AD with amyloid biomarker confirmation through either CSF amyloid beta₁₋
105 ₄₂ (A β ₄₂) analysis or amyloid-PET [1]. ADC controls had subjective cognitive decline,
106 defined as cognitive complaints without objective cognitive impairment on
107 neuropsychological exam, no signs of neurodegeneration on neuroimaging, and
108 absence of AD pathology based on CSF biomarkers and/or amyloid-PET. Exclusion
109 criteria for all participants were ophthalmological conditions interfering with retinal
110 scan quality, e.g. diabetic retinopathy, glaucoma or moderate/intermediate age
111 related macular degeneration.. In addition, we excluded subjects with ischemic stroke
112 and/or mild to severe white matter hyperintensities on MRI, operationalized as a
113 Fazekas score > 2 . We excluded two AD patients; one because of problems with eye
114 fixation due to visuoperceptive dysfunction and one because of participation in a drug
115 trial with disease modifying drugs. We excluded two controls; one due to problems
116 finishing the scan protocol because of dry eyes and one was found to have
117 glaucoma. Three AD patients were lost to follow up. This study was designed and

118 conducted according to the Declaration of Helsinki and the study protocol was
119 approved by the Ethical Committee of the VU University Medical Center. All patients
120 gave their written informed consent in the presence of their caregiver.

121

122 *Amyloid biomarker assessment*

123 Between 2016 and 2018, CSF concentrations of A β ₄₂, total tau, and tau
124 phosphorylated at threonine 181 (pTau₁₈₁) were measured using Innotech ELISAs
125 (Fujirebio, Ghent, Belgium). Between 2018 and 2020, these CSF biomarkers were
126 assessed using Elecsys A β ₁₋₄₂ CSF, Elecsys total-tau CSF, and Elecsys pTau₁₈₁
127 CSF electrochemiluminescence immunoassays (Roche Diagnostics, Basel,
128 Switzerland). For comparability Innotech CSF values were converted using previously
129 published conversion formulas [17]. A pTau/ A β ₄₂-ratio \geq 0.020 was considered an AD
130 profile [18].

131 Amyloid-PET scanning was performed with either ¹⁸F-Florbetaben (NeuraCeq), ¹⁸F-
132 Florbetapir (Amyvid) or ¹⁸F-Flutemetamol (Vizamyl) tracers [19-21]. An experienced
133 nuclear physician (BvB) who completed training for all radiotracers visually assessed
134 images of amyloid-PET scans as positive or negative.

135

136 *Ophthalmological assessment*

137 Subjects underwent the following general eye examination: best corrected visual
138 acuity (VA), intraocular pressure (IOP) using non-contact tonometry, and slit-lamp
139 examination of the anterior and posterior segment, followed by administration of
140 tropicamide 0.5% to dilate the pupil for optimal retinal imaging. An experienced
141 ophthalmologist (FDV) interpreted all examinations.

142

143 *Heidelberg HRA SLO imaging*

144 Retinal fluorescence imaging was performed with a Heidelberg Engineering
145 Spectralis Spectral Domain Scanning Laser Ophthalmoscope, at a 486nm
146 wavelength (blue autofluorescence) laser source to excite fluorescence, in
147 combination with a long-pass 500 filter (high transmission in 498-760nm and 800-
148 835nm). Optical resolution was 12 μm with a 55° lens, and 6 μm with a 30° lens. For
149 each final image an average of 50 frames was used with a sensitivity >90.

150

151 *Curcumin administration and timing of fluorescence imaging*

152 Three different oral formulations of curcumin were used:

153 1. Longvida® Solid-Lipid Curcumin Particle (Verdure Sciences®), was given in a
154 dosage of 4000 mg per day for 10 consecutive days to 14 AD patients and 12
155 controls [7]. Here we used a 30° lens to acquire images in six regions of interest
156 (ROI) (central macula, superior, temporal, inferior, superior-temporal and inferior-
157 temporal) at baseline and 2-4 hours after the 10th day of curcumin intake (Figure 1A-
158 B).

159 2. Theracurmin® (Theracurmin; Theravalues, Tokyo, Japan), was given in a dosage
160 of 180 mg for 5 consecutive days to 7 AD patients and 2 controls [22, 23]. Here we
161 acquired images using a 30° lens in three ROI's (central macula, optic nerve head
162 (ONH) and temporal) at four different time points: i) at baseline, ii) after four days of
163 curcumin intake, iii) 1 hour after the fifth dose, and iv) 2 hours after the fifth dose
164 (Figure 1 A-B).

165 3. Novasol® (AQUANOVA AG, Darmstadt, Germany), was given in a dosage of 300
166 mg for 4 consecutive days and a final dose of 500 mg on day 5 to 5 AD patients [24,
167 25]. With Novasol we acquired images using a 55° lens in six ROI's (central macula,

168 superior, temporal, inferior, superior-temporal and inferior-temporal) at baseline and 2
169 hours after the fifth dose (Figure 1A-B).

170

171 *Retinal fluorescence image analysis*

172 Baseline and post-curcumin-administration images were assessed both visually and
173 quantitatively. Visual assessment was performed by an experienced ophthalmologist,
174 masked for diagnosis and curcumin treatment (FDV). Baseline and post-curcumin-
175 administration images of AD patients were compared for the Novasol cohort and also
176 between AD and control subjects for the Theracurmin and Longvida cohort. To
177 support the visual assessment, we used the Longvida[®] cohort for quantitative
178 analysis, allowing comparison to previous publications using Longvida[®] as curcumin
179 derivative. Images of the right eye with sufficient image quality (scans that were out
180 of focus, had extensive shading or extreme low/high contrast hampering co-
181 registration were excluded) were assessed for quantitative analysis (Figure 1C).

182 Retinal fluorescence imaging yielded 8-bit grayscale images sized 1536 x 1566 or
183 768 x 798 pixels with a resolution of 6 or 12 μm respectively per pixel. The non-
184 normalized, uncompressed images were compared between time points using
185 MATLAB 2020b (MathWorks). An image pair of two time points of similar ROI's were
186 cropped to a size of 1430 x 1430 or 715 x 715 pixels to remove the manufacturer
187 logo and blurry edges. In the case any image pair contained high resolution images
188 (1430 x 1430) the images were down-sampled to match the size of 715 x 715 pixels.
189 Afterwards, both images were flat-field corrected to compensate for any illumination
190 and shading effect. A registration algorithm (feature-based registration (SURF:
191 Speeded-Up Robust Features) with affine transformation, allowing for rotation) was
192 used to register matched images [26]. If an automatic match was not obtained, the

193 software interrupted and allowed for manual picking of identical points of interest in
194 both images and creating a registration match based on the user's input (using the
195 same registration algorithm). Registered images were cropped to a size of 512 x 512
196 pixels, ensuring that both images overlapped within the imaged field of view.
197 Brightness histograms of both images were obtained and matched (using a cubic
198 polynomial) to the histogram of the baseline image, resulting in images with similar
199 contrast and overall brightness. We defined focal retinal hyperfluorescence, by
200 selecting areas of ≥ 4 adjacent pixels that represented the 10% highest pixel value in
201 the post-curcumin image. These hyperfluorescence spots were labeled, and their
202 area and brightness measured. The same properties were measured in the baseline
203 image, using the exact same spots (as identified in the post-curcumin image).
204 Afterwards, the brightness difference between each hyperfluorescence spot was
205 calculated.

206

207 *Curcuminoids plasma level analysis*

208 Blood was drawn in heparinized tubes that were directly kept in aluminum foil on ice,
209 to avoid degradation by light and temperature. Within 30 minutes, plasma and serum
210 were separated and plasma was stored at minus 80°C in the Amsterdam UMC
211 Biobank. High Performance Liquid Chromatography-Tandem Mass Spectroscopy
212 (HPLC-MS-MS) analysis was performed to measure different curcuminoids:
213 curcumin, demethoxycurcumin, bisdemethoxycurcumin and tetrahydrocurcumin.
214 Each sample was treated, in duplicates, with and without β -glucuronidase after which
215 unconjugated and conjugated curcuminoids were quantified. Treatment with β -
216 glucuronidase hydrolyzes the conjugated curcuminoids leading to an increase in
217 unconjugated curcuminoids, whereas untreated samples were quantified on

218 unconjugated curcumin at that point of time. Our validated method of analysis can be
219 described, in short, as follows: Liquid-liquid extraction with Tert Butyl Methyl Ether
220 (TBME) was used to extract the compounds from the plasma [27]. The HPLC-MS/MS
221 system consisted of an Ultimate 3000 autosampler and pump, both of Dionex,
222 connected to a degasser from LC Packings. The autosampler, with a 100 μ L sample
223 loop, was coupled to an Sciex API4000 mass spectrometer. A total of 50 μ L sample
224 was injected after which separation of the analytes was performed with an Agilent
225 column 2.1x100mm packed with material of Zorbax Extend 3.5 μ m C-18. The
226 flowrate was 0.200 μ L/min and the dual gradient mobile phase consisted of A: ultra-
227 purified H₂O with 0.1% formic acid and B: MeOH 100%. The applied gradient profile
228 started at 50:50 A:B and increased linear to 95% B in 3.0 minutes. During 6 minutes
229 a 5:95 A:B level is continued, after which it returned in 0.2 minutes to 50:50.
230 Afterwards the system was equilibrated during 6 minutes at the starting level.
231 Throughout the liquid-liquid extraction and HPLC-MS/MS the potential influence of
232 light brought back to a minimum by working in a dark environment. Each analytical
233 run included a set of freshly prepared calibration samples containing all compounds
234 in the validated range of 2 nM to 400 nM. Each compound was validated with its own
235 deuterated internal standard.

236

237 *Statistical analysis*

238 SPSS version 26.0 (IBM, Armonk, NY, USA) was used to assess group differences in
239 demographics, curcumin data and quantitative retinal fluorescence. Chi squared test
240 was used for dichotomous variables, independent sample T-test was used for
241 continuous variables that were normally distributed and Mann Whitney U Test was
242 used for non-normal distributed variables. Quantitative comparison of focal retinal

243 hyperfluorescence between AD patients and controls was assessed by calculating
244 the number of focal retinal hyperfluorescent pixels defined as a value in the top 10%
245 value range at baseline and after curcumin, for all retinal regions of the right eye.
246 Between group differences were assessed using a Mann Whitney U test.
247 Significance level for all tests was set at 0.05.

248

249 **Results**

250 Group demographics of AD and control cases are shown in table 1, and
251 supplemental table 1 shows data for each individual participant. The control group
252 comprised more female participants. No differences were found for age between AD
253 and control group. As expected, and by design, we found significant group
254 differences for MMSE as well as CSF and amyloid-PET biomarkers. Table 2A shows
255 the demographics of the sub group used for the quantitative analysis. No statistical
256 group differences in age and sex were found.

257

258 *Qualitative and quantitative retinal fluorescence analysis*

259 No scans were excluded for the qualitative analysis. The qualitative assessment of
260 images pre- and post-curcumin intake by an experienced ophthalmologist (FDV)
261 masked for the clinical diagnosis did not show differences in focal hyperfluorescence
262 in the ROI's, for either AD patients (Longvida[®], Theracurmin[®] and Novasol[®]) or
263 controls (Longvida[®] and Theracurmin[®])(Figure 2 and supplemental Figures 1 and 2).
264 The Longvida[®] cohort was used for quantitative analysis. For the quantitative
265 analysis one out of 12 control cases (case #10, see Supplemental Table 1) was
266 excluded, as our algorithms were unable to find a good registration between time
267 points. This applied to a total of 24 regions of a total of 10 patients, while the other

268 regions (n=132) could be included in the analysis. All 14 AD cases that used
269 Longvida® were included in the quantitative analysis. While we did find an overall
270 increased fluorescence after curcumin intake (data not shown), no differences were
271 found between diagnostic groups in the number of spots with increased or decreased
272 fluorescence after curcumin intake for all ROIs (all p-values>0.3) (Table 2B).

273

274 *Curcuminoids plasma level analysis*

275 HPLC-MS/MS analysis of plasma samples showed detectable levels of free curcumin
276 in blood around the detection level (2 nM) after Longvida®, Theracurmin® or Novasol®
277 intake in all 40 subjects, however there were no significant differences between
278 groups. After treating the samples with β -glucuronidase, catalyzing the separation of
279 curcumin from glucuronide and sulfate conjugates, curcumin levels were higher
280 (Table 3). The total mean of curcuminoids was 156.2 nM (\pm 169.9) after Longvida®,
281 576.6 nM (\pm 211.1) after Theracurmin® and 1605.8 nM (\pm 524.6 nM) after Novasol®
282 (Figure 3). There were no differences in plasma levels between diagnostic groups (p
283 >0.3, data not shown).

284

285 **Discussion**

286 In this study we aimed to discriminate AD patients from controls with a targeted
287 fluorescence approach of the retina using curcumin as fluorophore in a well-
288 characterized AD biomarker confirmed cohort. Using three different curcumin
289 formulations, we did not find differences in focal retinal hyperfluorescence before or
290 after curcumin intake between diagnostic groups, despite an observed overall
291 increase in retinal fluorescence after curcumin intake.

292 Our negative findings may be explained by a low intensity of the fluorescent signal
293 resulting from (amyloid-bound) curcumin, insufficient binding of unconjugated
294 curcumin to retinal amyloid, absence of retinal amyloid (in this subset of patients) or
295 methodological limitations of our scanning and analysis methods.
296
297 Fluorescence of curcumin largely overlaps with autofluorescence of the retina. This
298 might therefore mask subtle signals of curcumin fluorescence hypothesized to be the
299 result of retinal amyloid (plaque) pathology, reported to be approximately 5-20 μ m in
300 size [7]. At present no data is available describing the magnitude of fluorescent signal
301 that can be expected from retinal amyloid relative to retinal autofluorescence. On
302 visual inspection we could identify a certain number of hyperfluorescent spots (Figure
303 3, zoom-ins), however there was no difference between AD patients and controls in
304 these spots, either in size or intensity, neither at baseline, nor after curcumin intake.
305 To increase sensitivity for weak retinal fluorescent signal possibly overlooked by
306 visual inspection, we performed a quantitative analysis on a subset of participants (14
307 AD, 11 controls) who received Longvida confirming findings of the visual inspection.
308
309 The absence of a fluorescent signal after curcumin intake could also be explained by
310 insufficient curcumin binding to retinal amyloid due to low plasma levels of
311 unconjugated curcumin. After deconjugation using β -glucuronidase we observed
312 high blood levels of total curcumin, in line with previous studies [22, 24]. In contrast,
313 Koronyo *et al.* found high levels of unconjugated curcumin (400nM) without using β -
314 glucuronidase [7]. This could be attributed to their different analysis methods: 1.
315 wider/broader calibration settings. 2. internal standards without deuterated forms and
316 validated in mouse. 3. acidification instead of freezing to stabilize samples .

317 Nevertheless, conjugated forms of curcumin are known to bind to amyloid as well
318 following ex-vivo application to post-mortem brain sections [28]. And penetration of
319 curcumin in the retina is suggested by our quantitative analysis where a general
320 increase in fluorescence was observed after curcumin intake (data not shown),
321 implying that curcumin with the capacity to bind fibrillar amyloid reached the retina.
322 Despite 3-4 times higher plasma levels of curcumin conjugates using Theracurmin®
323 and Novasol® compared to Longvida® in this study, we found no difference in focal
324 retinal hyperfluorescence between AD patients and controls.

325

326 The lack of between-group differences in our study could also be explained by
327 absence of amyloid in the retina. The presence of (fibrillar) amyloid in the human
328 retina is not unequivocally proven, as three labs showed positive staining with 6E10
329 and 12F4 antibodies interpreted as presence of retinal amyloid plaques in post-
330 mortem retinas, while others were unable to replicate these findings [7, 10, 12, 13,
331 29, 30]. Methodological heterogeneity in post-mortem study methods might account
332 for these discrepancies. Replication studies and harmonization of study methods are
333 needed to overcome these discrepancies before the presence of retinal amyloid in
334 AD can undoubtedly be confirmed. This is one of the key goals of 'The Eye as a
335 Biomarker for AD' Personal Interest Area of the Alzheimer's Association.

336

337 Three previous studies showed hyperfluorescence in AD cases after curcumin intake
338 [7-9]. While these studies were of similar small sample size, AD biomarker
339 confirmation was lacking, which is essential when relating retinal changes to AD,
340 since other structures may cause changes in fluorescence as well. For example,
341 retinal drusen, associated with macular degeneration, contain amyloid and other age-

342 related deposits [31, 32]. This may account for the positive findings in Koronyo's
343 study where AD patients had a mean age of 76 years compared to 53 years in
344 controls [7]. More work is needed to discriminate normal aging from pathological
345 neurodegenerative changes in the retina underlying the observed changes in retinal
346 fluorescence.

347

348 There are some limitations of this study, potentially explaining the negative findings.
349 First, our scan timing might have been suboptimal for measuring curcumin bound to
350 retinal amyloid resulting in impaired sensitivity. The optimal time point to measure
351 retinal fluorescence is still to be determined. We based our scan timing on previously
352 published pharmacokinetic curves of systemically available curcumin representing
353 assumed peak levels of systemic curcumin, as has been shown to yield signal before
354 [7, 22-25]. Second, the quantitative analysis could not be applied on the full cohort
355 because of variation in imaging protocols. Also the fluorescent signal itself, is directly
356 affected by illumination differences within images and between time points. These
357 small alterations in scan quality may affect the co-registration of baseline and follow
358 up scans and the signal itself. We applied several algorithms correcting for
359 differences in illumination and scan quality. We are open to sharing our raw data,
360 enabling application of other algorithms.

361

362 In conclusion, we found no differences in focal retinal hyperfluorescence between AD
363 patients and controls pre- and post-curcumin, using Longvida[®], a curcumin
364 formulation previously used for this purpose. As we could not replicate previous
365 findings with similar methods in our amyloid biomarker-confirmed cohort, we question
366 whether focal retinal hyperfluorescence represents retinal amyloid, or rather age-

367 related changes. Based on our analysis, retinal hyperfluorescence imaging using
368 oral curcumin as labeling fluorophore is currently not ready for use as AD biomarker.
369

370 References

- 371 1. Jack, C.R., Jr., et al., *NIA-AA Research Framework: Toward a biological*
372 *definition of Alzheimer's disease*. *Alzheimers Dement*, 2018. **14**(4): p. 535-
373 562.
- 374 2. Sperling, R.A., et al., *Toward defining the preclinical stages of Alzheimer's*
375 *disease: recommendations from the National Institute on Aging-Alzheimer's*
376 *Association workgroups on diagnostic guidelines for Alzheimer's disease*.
377 *Alzheimers Dement*, 2011. **7**(3): p. 280-92.
- 378 3. Scheltens, P., et al., *Alzheimer's disease*. *Lancet*, 2021. **397**(10284): p. 1577-
379 1590.
- 380 4. Alber, J., et al., *Developing retinal biomarkers for the earliest stages of*
381 *Alzheimer's disease: What we know, what we don't, and how to move forward*.
382 *Alzheimers Dement*, 2020. **16**(1): p. 229-243.
- 383 5. Gupta, V.B., et al., *Retinal changes in Alzheimer's disease- integrated*
384 *prospects of imaging, functional and molecular advances*. *Prog Retin Eye Res*,
385 2021. **82**: p. 100899.
- 386 6. Snyder, P.J., et al., *Retinal imaging in Alzheimer's and neurodegenerative*
387 *diseases*. *Alzheimers Dement*, 2021. **17**(1): p. 103-111.
- 388 7. Koronyo, Y., et al., *Retinal amyloid pathology and proof-of-concept imaging*
389 *trial in Alzheimer's disease*. *JCI Insight*, 2017. **2**(16).
- 390 8. Tadokoro, K., et al., *Retinal Amyloid Imaging for Screening Alzheimer's*
391 *Disease*. *J Alzheimers Dis*, 2021.
- 392 9. Ngolab, J., et al., *Feasibility study for detection of retinal amyloid in clinical*
393 *trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4)*
394 *trial*. *Alzheimers Dement (Amst)*, 2021. **13**(1): p. e12199.
- 395 10. den Haan, J., et al., *Amyloid-beta and phosphorylated tau in post-mortem*
396 *Alzheimer's disease retinas*. *Acta Neuropathol Commun*, 2018. **6**(1): p. 147.
- 397 11. Jiang, J., et al., *Amyloid Plaques in Retina for Diagnosis in Alzheimer's*
398 *Patients: a Meta-Analysis*. *Front Aging Neurosci*, 2016. **8**: p. 267.
- 399 12. Williams, E.A., et al., *Absence of Alzheimer Disease Neuropathologic*
400 *Changes in Eyes of Subjects With Alzheimer Disease*. *J Neuropathol Exp*
401 *Neurol*, 2017. **76**(5): p. 376-383.
- 402 13. Ho, C.Y., et al., *Beta-amyloid, phospho-tau and alpha-synuclein deposits*
403 *similar to those in the brain are not identified in the eyes of Alzheimer's and*
404 *Parkinson's disease patients*. *Brain Pathol*, 2014. **24**(1): p. 25-32.
- 405 14. Schon, C., et al., *Long-term in vivo imaging of fibrillar tau in the retina of*
406 *P301S transgenic mice*. *PLoS One*, 2012. **7**(12): p. e53547.
- 407 15. Konijnenberg, E., et al., *The EMIF-AD PreclinAD study: study design and*
408 *baseline cohort overview*. *Alzheimers Res Ther*, 2018. **10**(1): p. 75.
- 409 16. van der Flier, W.M. and P. Scheltens, *Amsterdam Dementia Cohort:*
410 *Performing Research to Optimize Care*. *J Alzheimers Dis*, 2018. **62**(3): p.
411 1091-1111.
- 412 17. Willemse, E.A.J., et al., *Diagnostic performance of Elecsys immunoassays for*
413 *cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic,*
414 *multicenter memory clinic cohort: The ABIDE project*. *Alzheimers Dement*
415 *(Amst)*, 2018. **10**: p. 563-572.
- 416 18. Willemse, E.A.J., et al., *Comparing CSF amyloid-beta biomarker ratios for two*
417 *automated immunoassays, Elecsys and Lumipulse, with amyloid PET status*.
418 *Alzheimers Dement (Amst)*, 2021. **13**(1): p. e12182.

- 419 19. Barthel, H., et al., *Cerebral amyloid- β PET with florbetaben (18F) in patients*
420 *with Alzheimer's disease and healthy controls: a multicentre phase 2*
421 *diagnostic study*. *Lancet Neurol*, 2011. **10**(5): p. 424-35.
- 422 20. Clark, C.M., et al., *Use of florbetapir-PET for imaging beta-amyloid pathology*.
423 *JAMA*, 2011. **305**(3): p. 275-83.
- 424 21. Curtis, C., et al., *Phase 3 trial of flutemetamol labeled with radioactive fluorine*
425 *18 imaging and neuritic plaque density*. *JAMA Neurol*, 2015. **72**(3): p. 287-94.
- 426 22. Kanai, M., et al., *A phase I study investigating the safety and*
427 *pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer*
428 *patients*. *Cancer Chemother Pharmacol*, 2013. **71**(6): p. 1521-30.
- 429 23. Sasaki, H., et al., *Innovative preparation of curcumin for improved oral*
430 *bioavailability*. *Biol Pharm Bull*, 2011. **34**(5): p. 660-5.
- 431 24. Schiborr, C., et al., *The oral bioavailability of curcumin from micronized*
432 *powder and liquid micelles is significantly increased in healthy humans and*
433 *differs between sexes*. *Mol Nutr Food Res*, 2014. **58**(3): p. 516-27.
- 434 25. Kocher, A., et al., *Highly bioavailable micellar curcuminoids accumulate in*
435 *blood, are safe and do not reduce blood lipids and inflammation markers in*
436 *moderately hyperlipidemic individuals*. *Mol Nutr Food Res*, 2016. **60**(7): p.
437 1555-63.
- 438 26. Bay, H., T. Tuytelaars, and L. Van Gool. *SURF: Speeded Up Robust Features*.
439 *in Computer Vision – ECCV 2006*. 2006. Berlin, Heidelberg: Springer Berlin
440 Heidelberg.
- 441 27. Kroon, M.A.G.M.v.L., H.W.M.; Swart, E.L. Kemper, E. Marleen; van Tellingem,
442 Olaf, A *Validated Hplc-Ms/Ms Method for Simultaneously Analyzing*
443 *Curcuminoids, Tetrahydrocurcumin and Piperine in Human Plasma, Urine or*
444 *Feces*. Available at SSRN: <https://ssrn.com/abstract=4077493> or
445 <http://dx.doi.org/10.2139/ssrn.4077493>. SSRN, 2022.
- 446 28. den Haan, J., et al., *Different curcumin forms selectively bind fibrillar amyloid*
447 *beta in post mortem Alzheimer's disease brains: Implications for in-vivo*
448 *diagnostics*. *Acta Neuropathol Commun*, 2018. **6**(1): p. 75.
- 449 29. Grimaldi, A., et al., *Neuroinflammatory Processes, A1 Astrocyte Activation and*
450 *Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible*
451 *Biomarkers for Early Diagnosis*. *Front Neurosci*, 2019. **13**: p. 925.
- 452 30. Tsai, Y., et al., *Ocular changes in TgF344-AD rat model of Alzheimer's*
453 *disease*. *Investigative ophthalmology & visual science*, 2014. **55**(1): p. 523-
454 534.
- 455 31. Luibl, V., et al., *Drusen deposits associated with aging and age-related*
456 *macular degeneration contain nonfibrillar amyloid oligomers*. *J Clin Invest*,
457 2006. **116**(2): p. 378-85.
- 458 32. Bergen, A.A., et al., *On the origin of proteins in human drusen: The meet,*
459 *greet and stick hypothesis*. *Prog Retin Eye Res*, 2019. **70**: p. 55-84.

461

462 **Authors' contributions**

Author	Contributions
Jurre den Haan	Literature search, study design, data collection, data analysis, data interpretation, figures, writing-original draft. Verified data.
Frederique Hart de Ruyter	Data collection, data analysis, data interpretation, writing-review and editing
Benjamin Lochocki	Image analysis, quantitative data analysis, data interpretation, writing-review and editing
Maurice A.G.M. Kroon	Data collection plasma analysis, data analysis, data interpretation, writing-original draft
Marleen E. Kemper	Methodology plasma analysis, writing-review and editing, supervision
Charlotte E. Teunissen	Biomarker data interpretation, writing-review and editing
Bart van Berckel	Biomarker data interpretation, writing-review and editing
Philip Scheltens	Funding acquisition, writing-review and editing
Jeroen J. Hoozemans	Data interpretation, writing-review and editing
Aleid Kreeke	Data collection
Frank D. Verbraak	Methodology, study design, image data collection, data analysis, data interpretation, writing-review&editing. Verified data.
Johannes F. de Boer	Funding acquisition, methodology, study design, data interpretation, writing-review and editing. Verified data.
Femke H. Bouwman	Funding acquisition, study design, data analysis, data interpretation, writing-original draft. Verified data.

463

464

465

466 **Conflicts of interest**

467 Research of CT is supported by the European Commission (Marie Curie International
468 Training Network, grant agreement No 860197 (MIRIADE), and JPND), Health
469 Holland, the Dutch Research Council (ZonMW), Alzheimer Drug Discovery
470 Foundation, The Selfridges Group Foundation, Alzheimer Netherlands, Alzheimer
471 Association. CT is recipients of ABOARD, which is a public-private partnership
472 receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life
473 Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners
474 participate in ABOARD. ABOARD also receives funding from Edwin Bouw Fonds and
475 Gieskes-Strijbisfonds. CT has a collaboration contract with ADx Neurosciences,
476 Quanterix and Eli Lilly, performed contract research or received grants from AC-
477 Immune, Axon Neurosciences, Biogen, Brainstorm Therapeutics, Celgene, EIP
478 Pharma, Eisai, PeopleBio, Roche, Toyama, Vivoryon. FB has a collaboration
479 contract with Biogen, Optina Dx and Roche. Payments are made to the institution of
480 VUMC. FB is committee member of EAN and chairs the atypical AD PIA and the Eye
481 as biomarker for AD PIA of ISTAART. PS is chair steering committee in NOVARTIS,
482 member DSMB GENENTECH, global PI phase s! study AC IMMUNE, member
483 advisory board AXON NEUROSCIENCE, global PI phase 2B study EIP PHARMA, PI
484 phase 2B study COGRX, member advisory board GEMVAX, COGNOPTIX and
485 CORTEXZYME, member strategic innovation committee GREEN VALLEY, PI global
486 phase 2B study Vivoryon, PI global phase 2A study TOYAMA / FUJI FILM, PI global
487 phase 1A study IONIS, personal fees from Life Science Partners Amsterdam,
488 outside the submitted work. JB is supported for the current study by NWO
489 (Foundation for scientific research in the Netherlands, similar to NIH and NSF) and
490 Co-financing by Heidelberg engineering as part of the competitive research proposal,

491 administered by the funding agency. Both these fundings are paid to institution.
492 Besides this study JB received past 36 months research grants from Heidelberg, TKI,
493 TNO, LSHM paid to institution. Personal fees from royalties through former employer,
494 Massachussets general Hospital, for IP that has been licensed to Terumo,
495 Heidelberg engineering and Spectrawave as well as fees for expert witness for a UK
496 based law firm. He is program committee member for a number of conferences,
497 unpaid. JdH, FH, MK, MK, BB, JH, AK, FV report no conflict of interest

498

499 **Acknowledgements/Funding**

500 We gratefully acknowledge financial support from Stichting Alzheimercentrum VUMC,
501 Alzheimer Nederland, the Dutch Technology Foundation STW (grant number 13935),
502 part of the Netherlands Organization for Scientific Research (NWO), and which is
503 partly funded by the Ministry of Economic Affairs, ISAO (grant number 14518).

504

505 **Data availability**

506 Raw imaging and clinical data is available upon request

507

508 **Key Words**

509 Biomarker, retina, curcumin, amyloid, Alzheimer's disease

510

511 **Tables**

512 **Table 1. Demographics**

	Alzheimer's disease <i>n</i> = 26	Controls <i>n</i> = 14	p-value
Sex (F/M)	10/16	10/4	.047 ^a
Age, mean (SD)	67 (9)	71 (12)	.177 ^b
MMSE, median (IQR)	24 (21-26)	29 (29-30)	.000 ^c
CSF Aβ, median (IQR)	541 (466-744)	1328 (982-1551)	.002 ^c
CSF Tau, median (IQR)	320 (242-472)	208 (123-322)	.060 ^c
CSF pTau, median (IQR)	34 (23-44)	19 (9-30)	.035 ^c
CSF biomarker profile (positive/negative)	20/0	3*/2	.033 ^a
Amyloid-PET (visual read: positive/negative)	17/0	0/13	.000 ^a

513

514 CSF data (presented as pg/ml) was available in 20 AD cases and 5 controls.

515 Amyloid-PET data (visual read) was available in 17 AD cases and 13 controls. ^aChi

516 squared test, ^bIndependent sample T-test, ^cMann Whitney-U test. *3 controls had a

517 borderline positive biomarker profile, with a negative amyloid-PET. Abbreviations: SD

518 = standard deviation; MMSE = mini mental state exam; IQR = interquartile range;

519 pTau = phosphorylated tau; CSF = cerebral spinal fluid.

520

521 **Table 2**
522 **A) Demographics Longvida® Subgroup Quantitative analysis**

	AD n = 14	CN n = 11	p-value
Sex (F/M)	6/8	7/4	0.302 ^a
Age, mean (SD)	71(9)	73(11)	0.405 ^b
MMSE, median (IQR)	24(19-30)	29(27-30)	<0.001 ^c
CSF A β , median (IQR)	560(322-805)	1198(641-1498)	0.048 ^c
CSF Tau, median (IQR)	295(108-551)	247(136-364)	0.683 ^c
CSF pTau, median (IQR)	31(11-33)	22(11-33)	0.461 ^c
Amyloid-PET (visual read): (positive/negative)	7/0	0/11	<0.001 ^a

523

524 **B) Quantitative analysis**
525

Number of increased spots	AD		CN		p-value
	Mean	SD	Mean	SD	
Macula	29.5	23.4	46.5	51.7	0.748
Temporal	40.5	28.2	47.8	45.3	0.809
Inferior	52.6	62.0	37.9	46.1	0.705
Inferior-Temporal	33.3	22.0	28.0	28.9	0.403
Superior	39.1	47.4	29.2	25.2	0.905
Superior-Temporal	44.4	35.6	44.6	36.7	1.000

526

527

Number of decreased spots	AD		CN		p-value
	Mean	SD	Mean	SD	
Macula	3.8	6.6	8.3	17.4	0.949
Temporal	8.9	12.3	8.9	16.1	0.647
Inferior	8.8	15.0	6.7	13.2	0.918
Inferior-Temporal	5.2	9.8	4.7	6.0	0.926
Superior	6.3	7.9	3.9	5.4	0.497
Superior-Temporal	11.2	11.0	9.3	8.4	0.896

528

529 A) CSF data (presented as pg/ml) was available in 8 AD cases and 4 controls.
530 Amyloid-PET data (visual read) was available in 7 AD cases and 12 controls. aChi
531 squared test, bIndependent sample T-test, cMann Whitney-U test. *3 controls had a
532 borderline positive biomarker profile, with a negative amyloid-PET. Abbreviations: AD
533 = Alzheimer's disease, CN =Controls, SD = standard deviation; MMSE = mini mental
534 state exam; IQR = interquartile range; pTau = phosphorylated tau; CSF = cerebral
535 spinal fluid.

536 B) Results of quantitative analyses of images obtained with 30-degree lens showing
537 the number of spots with and increased or decreased pixel value after Longvida®
538 curcumin intake compared to baseline in all retinal regions for 14 AD and 12 control
539 participants. Data is presented as mean and standard deviations. Group comparisons
540 were made using a Mann Whitney U Test.

541
542

543 **Table 3. Curcuminoids plasma levels**


	Longvida [®]	Theracurmin [®]	Novasol [®]
Curcumin	75.1 (70.2)	321.80 (146.1)	1108.40 (503.3)
Demethoxycurcumin	55 (62.5)	19.49 (9.7)	58.72 (28.6)
Bisdemethoxycurcumin	13.7 (12.1)	0.66 (0.3)	3.23 (2.4)
Tetrahydrocurcumin	43.6 (44.9)	234.70 (95.5)	435.4 (73.8)
Total curcuminoids	156.2(169.6)	576.6 (211.1)	1605.8 (524.6)

544
545 Plasma levels (mean \pm SD) of different curcuminoids (curcumin, demethoxycurcumin,
546 bisdemethoxycurcumin and tetrahydrocurcumin) and total curcuminoids after β -
547 glucuronidase treatment in nanomolar (nM). Time points for serum level
548 measurement after the start of curcumin intake were 10 days for Longvida[®] and 5
549 days for Theracurmin[®] and Novasol[®].

550

551 **Figures**

552




553

554

555 **Figure 1. Visual representation of study protocol**

556 A. Timing of imaging, blood draw and curcumin intake of cohort 1 (Longvida[®], 4000
 557 mg for 10 days), cohort 2 (Theracurmin[®], 180 mg for 5 days) and cohort 3 (Novasol[®],
 558 300 mg for 4 days, 500 mg for 1 day). B. Imaging protocol of cohort 1, 2 and 3. C.
 559 Quantitative analysis.


560



561

562 **Figure 2. Pre- and post-curcumin retinal fluorescence images for AD and control participants using Longvida®**

563 Pre-and post-curcumin retinal fluorescence images using blue auto fluorescence ($\lambda=486\text{nm}$) in 6 retinal regions in a representative
 564 AD patient and control. Magnifications show incidental focal hyperfluorescence, both on baseline and after curcumin in AD and
 565 control participants. Abbreviations: TS= temporal-superior, S= superior, T= temporal, M= macula, TI= temporal-inferior, I= inferior.



566

567 **Figure 3. Plasma levels of total curcuminoids after Longvida[®], Theracurmin[®]**

568 **and Novasol[®] intake measured with HPLC-MS/MS**

569 Overview of plasma levels of total curcuminoids after Longvida[®], Theracurmin[®] and

570 Novasol[®] intake. Curcumin, demethoxycurcumin, bisdemethoxycurcumin and

571 tetrahydrocurcumin as measured with HPLC-MS/MS after β -glucuronidase treatment,

572 summed as total curcuminoids in nanomolar (nM).

573


574 **Supplemental material**

575 **Supplemental table 1. Demographics for each individual participant**

#	Dx	Age	Sex	MMSE	CSF analysis				CSF assay	Amyloid-PET	Curcumin
					A β	Tau	pTau	pTau/A β			
1	AD	64	M	20	778	551	60	0.077	Elecsys	n.a.	Longvida
2	AD	57	M	23	342	108	10	0.029	Elecsys	n.a.	Longvida
3	AD	70	F	30	511	211	21	0.041	Elecsys	n.a.	Longvida
4	AD	72	M	22	805	316	35	0.043	Elecsys	n.a.	Longvida
5	CN	54	F	30	641	208	19	0.030	Elecsys	(-) 18F-Florbetapir	Longvida
6	AD	69	M	24	322	340	34	0.106	Elecsys	n.a.	Longvida
7	AD	56	F	21	746	215	23	0.031	Elecsys	n.a.	Longvida
8	CN	57	M	28	1323	136	11	0.008	Elecsys	(-) 18F-Florbetapir	Longvida
9	AD	59	F	19	337	156	17	0.050	Elecsys	n.a.	Longvida
10	CN	89	F	28	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
11	CN	70	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
12	AD	75	M	28	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
13	AD	79	M	27	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
14	AD	81	F	26	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
15	CN	80	M	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Florbetapir	Longvida
16	AD	77	M	25	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Flutemetamol	Longvida
17	AD	78	M	27	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
18	AD	81	M	27	n.a.	n.a.	n.a.	n.a.	n.a.	(+) 18F-Florbetaben	Longvida
19	CN	66	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
20	CN	82	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
21	CN	79	M	30	1328	279	26	0.020	Elecsys	(-) 18F-Florbetapir	Longvida
22	CN	78	F	27	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
23	CN	84	M	29	1498	364	33	0.022	Elecsys	(-) 18F-Florbetapir	Longvida
24	AD	77	F	23	642	460	45	0.070	Elecsys	(+) 18F-Flutemetamol	Longvida
25	CN	66	F	30	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
26	CN	76	F	29	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Flutemetamol	Longvida
27	AD	67	M	21	548	394	35	0.064	Innotest	(+) 18F-Florbetapir	Theracurmin
28	AD	61	M	20	738	307	31	0.042	Innotest	(+) 18F-Florbetaben	Theracurmin
29	CN	63	F	30	n.a.	n.a.	n.a.	n.a.	n.a.	(-) 18F-Florbetapir	Theracurmin
30	AD	64	M	18	291	847	67	0.231	Innotest	(+) 18F-Florbetaben	Theracurmin
31	AD	66	M	28	637	282	24	0.037	Innotest	(+) 18F-Florbetaben	Theracurmin
32	CN	51	F	30	1604	110	7	0.004	Innotest	n.a.	Theracurmin
33	AD	57	F	19	843	587	48	0.057	Innotest	(+) 18F-Florbetaben	Theracurmin
34	AD	61	M	25	456	367	40	0.088	Innotest	(+) 18F-Florbetaben	Theracurmin
35	AD	54	M	24	521	322	30	0.058	Innotest	(+) 18F-Florbetaben	Theracurmin
36	AD	69	M	25	693	318	35	0.051	Innotest	(+) 18F-Florbetaben	Novasol
37	AD	65	F	24	534	477	46	0.086	Innotest	(+) 18F-Florbetaben	Novasol
38	AD	60	M	18	497	232	23	0.047	Innotest	n.a.	Novasol
39	AD	56	F	23	892	486	33	0.037	Innotest	n.a.	Novasol
40	AD	55	F	24	525	270	25	0.048	Innotest	n.a.	Novasol

576
577 Cohort characteristics of participants enrolled in cohort 1 (Longvida®), cohort 2

578 (Theracurmin®) and cohort 3 (Novasol®). CSF data is presented as pg/ml. pTau/A β
579 ratio ≥ 0.020 was considered as AD profile.¹⁷ Abbreviations: # = Participant Number,
580 Dx =Diagnosis, MMSE = Mini-Mental State Examination, CSF = Cerebrospinal Fluid,
581 A β = Amyloid-beta, pTau = Phosphorylated Tau, + = positive, - = negative, n.a. = not
582 available.



584

585 **Supplemental Figure 1. Pre- and post-curcumin retinal fluorescence images for**
586 **AD patients and controls using Novasol®**

587 Pre-and post-curcumin retinal fluorescence images with a 55-degree lens using blue
588 auto fluorescence ($\lambda=486\text{nm}$) in 6 retinal regions in a representative Alzheimer's
589 disease (AD) patient. Abbreviations: TS= temporal-superior, S= superior, T=
590 temporal, M= macula, TI= temporal-inferior, I= inferior.

591

Alzheimer's Disease



592

593 **Supplemental Figure 2. Pre- and post-curcumin retinal fluorescence images for AD**
594 **patients and controls using Theracurmin®**

595 Pre-and post-curcumin retinal fluorescence images with a 30-degree lens using blue auto
596 fluorescence ($\lambda=486\text{nm}$) in 2 retinal regions in a representative Alzheimer's disease (AD)
597 patient and control. Abbreviations: M= macula, T= temporal.

598